二甲双胍联合胰岛素治疗2型糖尿病临床疗效观察

目的探讨二甲双胍联合胰岛素治疗2型糖尿病（T2DM）的治疗效果。方法选择已确诊为T2DM的患者110例，随机分为两组，A组为单纯胰岛素治疗，B组为二甲双胍加胰岛素治疗。所有患者均有使用胰岛素的适应症并且无使用二甲双胍的禁忌症，血清肌酐水平〈131umol／L，分别记录2组血糖达标时间，日胰岛素用量以及治疗前后的体重和糖化血红蛋白（HbAIc），空腹血糖（FPG），餐后两小时血糖（2HPG）变化。结果治疗前两组间FPG、2HPG、HbAIc及日胰岛素用量在统计学上均无显著性差异（P〉0.05），治疗后两组相比血糖达标时间、日胰岛素用量差异均非常显著（P〈0．01），体重改变和HbAIc的组之间进行比较差异显著（P〈0．05）。结论二甲双胍联合胰岛素治疗，优化降糖，安全达标。

Clinical Effect Observation of the Combined Treatment with Metformin and Insulin for Patients with Type 2 Diabetes

Objective To discuss the clinical effect of the combined treatment with Mefformin and insulin for patients with type 2 diabetes. Methods 110 cases with the final diagnosis of type 2 diabetes were randomly divided into 2 groups： Group A, receiving the treatment with insulin only and Group B, receiving the combined treatment with Mefformin and insulin; all the patients had the insulin indication and no Mefformin contraindication,their serum creafinine levels were 〈 131umol/L; the recording was made to the time for blood sugar reaching normal standard, the daily insulin quantity and the weight change, HbA1c, FPG and 2HPG before and after treatment. Results There was no significant difference of FPG, 2HPG, HbA1c and daily insulin quantity between the 2 groups before and after treatment （ P 〉 0.05） while an obvious difference of the time for blood sugar reaching normal standard and daily insulin quantity after treatment （ P 〈 0.01 ）, a significant difference of weight change and HbA1c between the 2 groups （ P 〈 0.05 ）. Conclusion The combined treatment of Mefformin and insulin is effective in reducing blood sugar safely.